Clinical Trial

Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma

Study acronym: GEMOXIA-02
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
We hypothesized that intra-arterial gemcitabine/oxaliplatin administered as second-line treatment could strongly improve objective response rate at 4 months after inclusion in patient with non-metastatic unresectable intra-hepatic cholangiocarcinoma.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2017-11-30; most recent amendment 2025-12-31.
Status change: Not Yet Recruiting → Recruiting 2020-01-07
Trial Details
NCT Number NCT03364530
Lead Sponsor University Hospital, Montpellier
Collaborators: Federation Francophone de Cancerologie Digestive
Conditions Cholangiocarcinoma Non-resectable, Non-metastatic
Enrollment 40 participants
Start Date 2018-06-11
Primary Completion 2025-10-21 (estimated)
Study Completion 2026-10-21 (estimated)
Updated on ClinicalTrials.gov 2026-01-05